Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The shift in the timing of revenue recognition to the second half or later, mainly for large projects; higher raw material and procurement costs; changes in the product mix; and lower sales in the medical and healthcare-related businesses.
There are no applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥12,690 million (YoY -1.2%) |
| Operating profit | ¥478 million (YoY -38.1%) |
| Ordinary income | ¥258 million (YoY -60.7%) |
| Profit attributable to owners of the parent | ¥-35 million (YoY -109.5%) |
| Net income per share | -¥2.00 |
| Equity ratio | End of the current fiscal period 37.2 / End of previous period 38.7 |
| Total assets | ¥44,024 million |
| Net assets | ¥16,433 million |
| Full-year earnings forecast | Net Sales ¥35,000 million (YoY +32.3%) / Operating profit ¥3,300 million (YoY +150.0%) / Ordinary income ¥3,000 million (YoY +145.6%) / Profit attributable to owners of the parent ¥2,000 million (YoY +50.8%) |
| Revision to Earnings Forecast | No (unchanged) |
| Annual Dividend Forecast | ¥40 → ¥45(+12.5%) |
| Segment revenue | Semiconductor and Mechatronics-Related Business ¥5,447 million (YoY +9.4%), Medical and Healthcare-Related Business ¥2,346 million (YoY -15.6%), Environmental and Social Infrastructure-Related Business ¥4,896 million (YoY -3.9%) |
| Segment profit | Semiconductor and Mechatronics-Related Business ¥498 million (YoY -33.3%), Medical and Healthcare-Related Business ¥4 million (YoY -96.8%), Environmental and Social Infrastructure-Related Business ¥408 million (YoY +34.3%) |
| Depreciation and amortization | ¥152 million |
| Impairment loss | Not applicable |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Other ¥0 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥2 million, Office relocation expenses ¥20 million, System-disruption response costs ¥17 million / Total special losses ¥39 million |
| Disclosure regarding the going concern assumption | There are no applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Newly included: 0 companies; excluded: 0 companies. 株式会社GDテック changed its fiscal year-end from 31 December to 31 March. |
| Material subsequent events | Effective 1 October 2026, an absorption-type merger will be carried out with the consolidated subsidiary ワイエイシイメカトロニクス株式会社 as the surviving company and ワイエイシイマシナリー株式会社 and 株式会社ワイエイシイダステック as the absorbed companies. The purpose is to integrate the Group's technologies, customer bases and human resources and deploy management resources in growth areas. The impact on consolidated results will be minor. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 19,517,894 shares |
| Treasury Shares at Period-End | 1,931,293 shares |
| Factors Behind Changes in Business Performance | The shift in the timing of revenue recognition to the second half or later, mainly for large projects; higher raw material and procurement costs; changes in the product mix; and lower sales in the medical and healthcare-related businesses. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The reasons cited were the shift in the timing of revenue recognition to the second half or later, mainly for large projects, higher raw material and procurement costs, changes in the product mix, and lower sales in the medical and healthcare-related businesses.